女性对男性的同种异体移植对结果的影响因单倍体移植类型的不同而不同。

IF 3.7 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cytotherapy Pub Date : 2025-02-01 DOI:10.1016/j.jcyt.2024.09.007

Masaharu Tamaki , Shunto Kawamura , Kosuke Takano , Hirohisa Nakamae , Noriko Doki , Hiroyuki Ohigashi , Yumiko Maruyama , Shuichi Ota , Nobuhiro Hiramoto , Tetsuya Eto , Satoshi Yoshihara , Ken-ichi Matsuoka , Masayoshi Masuko , Makoto Onizuka , Yoshinobu Kanda , Takahiro Fukuda , Yoshiko Atsuta , Ryu Yanagisawa , Kimikazu Yakushijin , Hideki Nakasone

{"title":"女性对男性的同种异体移植对结果的影响因单倍体移植类型的不同而不同。","authors":"Masaharu Tamaki , Shunto Kawamura , Kosuke Takano , Hirohisa Nakamae , Noriko Doki , Hiroyuki Ohigashi , Yumiko Maruyama , Shuichi Ota , Nobuhiro Hiramoto , Tetsuya Eto , Satoshi Yoshihara , Ken-ichi Matsuoka , Masayoshi Masuko , Makoto Onizuka , Yoshinobu Kanda , Takahiro Fukuda , Yoshiko Atsuta , Ryu Yanagisawa , Kimikazu Yakushijin , Hideki Nakasone","doi":"10.1016/j.jcyt.2024.09.007","DOIUrl":null,"url":null,"abstract":"<div><div>Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated. We investigated the impact of female-to-male allo-HCT according to the haplo-HCT subtype. In the post-transplant cyclophosphamide (PTCY) cohort (n = 660), a female-to-male sex-mismatch was significantly associated with a decreased risk of relapse (HR: 0.70 [95% CI: 0.49–0.99], <em>P</em> = 0.045), but not with overall survival (OS) or NRM (HR: OS 0.89 [95% CI: 0.68–1.16], <em>P</em> = 0.40; NRM 0.98 [95% CI: 0.68–1.41], <em>P</em> = 0.90). On the other hand, in the non-PTCY cohort (n = 219), a female-to-male sex-mismatch was associated with inferior risks of OS and NRM, but was not associated with relapse. These results suggested that the survival impact of the haplo-HCT subtype differed according to the presence of a sex-mismatch. PTCY might be feasible for overcoming the inferiority of female-to-male allo-HCT and might preserve a GVL effect against H-Y antigens.</div></div>","PeriodicalId":50597,"journal":{"name":"Cytotherapy","volume":"27 2","pages":"Pages 213-221"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation\",\"authors\":\"Masaharu Tamaki , Shunto Kawamura , Kosuke Takano , Hirohisa Nakamae , Noriko Doki , Hiroyuki Ohigashi , Yumiko Maruyama , Shuichi Ota , Nobuhiro Hiramoto , Tetsuya Eto , Satoshi Yoshihara , Ken-ichi Matsuoka , Masayoshi Masuko , Makoto Onizuka , Yoshinobu Kanda , Takahiro Fukuda , Yoshiko Atsuta , Ryu Yanagisawa , Kimikazu Yakushijin , Hideki Nakasone\",\"doi\":\"10.1016/j.jcyt.2024.09.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated. We investigated the impact of female-to-male allo-HCT according to the haplo-HCT subtype. In the post-transplant cyclophosphamide (PTCY) cohort (n = 660), a female-to-male sex-mismatch was significantly associated with a decreased risk of relapse (HR: 0.70 [95% CI: 0.49–0.99], <em>P</em> = 0.045), but not with overall survival (OS) or NRM (HR: OS 0.89 [95% CI: 0.68–1.16], <em>P</em> = 0.40; NRM 0.98 [95% CI: 0.68–1.41], <em>P</em> = 0.90). On the other hand, in the non-PTCY cohort (n = 219), a female-to-male sex-mismatch was associated with inferior risks of OS and NRM, but was not associated with relapse. These results suggested that the survival impact of the haplo-HCT subtype differed according to the presence of a sex-mismatch. PTCY might be feasible for overcoming the inferiority of female-to-male allo-HCT and might preserve a GVL effect against H-Y antigens.</div></div>\",\"PeriodicalId\":50597,\"journal\":{\"name\":\"Cytotherapy\",\"volume\":\"27 2\",\"pages\":\"Pages 213-221\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1465324924008867\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1465324924008867","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

将女性捐献者的异体造血干细胞移植给男性受者（女男同种异体血细胞移植）是导致慢性移植物抗宿主疾病（GVHD）和非复发死亡率（NRM）的公认风险因素。女男同种异体移植的不良结局被认为是由于H-Y抗原的同种免疫所致。然而，小组织相容性抗原在单倍体同种异体移植中的影响仍有待阐明。我们根据单倍体-HCT 亚型研究了女性-男性异体-HCT 的影响。在移植后环磷酰胺（PTCY）队列（n = 660）中，女男性别错配与复发风险降低显著相关（HR：0.70 [95% CI：0.49-0.99]，P = 0.045），但与总生存期（OS）或NRM无关（HR：OS 0.89 [95% CI：0.68-1.16]，P = 0.40；NRM 0.98 [95% CI：0.68-1.41]，P = 0.90）。另一方面，在非PTCY队列（n = 219）中，女性对男性的性别错配与较低的OS和NRM风险相关，但与复发无关。这些结果表明，单倍体-HCT亚型对生存的影响因性别错配的存在而不同。PTCY也许可以克服女男同种异体HCT的劣势，并可能保留针对H-Y抗原的GVL效应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation

Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated. We investigated the impact of female-to-male allo-HCT according to the haplo-HCT subtype. In the post-transplant cyclophosphamide (PTCY) cohort (n = 660), a female-to-male sex-mismatch was significantly associated with a decreased risk of relapse (HR: 0.70 [95% CI: 0.49–0.99], P = 0.045), but not with overall survival (OS) or NRM (HR: OS 0.89 [95% CI: 0.68–1.16], P = 0.40; NRM 0.98 [95% CI: 0.68–1.41], P = 0.90). On the other hand, in the non-PTCY cohort (n = 219), a female-to-male sex-mismatch was associated with inferior risks of OS and NRM, but was not associated with relapse. These results suggested that the survival impact of the haplo-HCT subtype differed according to the presence of a sex-mismatch. PTCY might be feasible for overcoming the inferiority of female-to-male allo-HCT and might preserve a GVL effect against H-Y antigens.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cytotherapy 医学-生物工程与应用微生物

CiteScore

6.30

自引率

4.40%

发文量

683

审稿时长

49 days

期刊介绍： The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.